source
- AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart diseaseResults published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
- Daiichi Sankyo to restructure its commercial organization, appointing Ken Keller as chief commercialization officerDaiichi Sankyo announced plans to overhaul its commercial operations, with a split of its commercialization activities slated for April 1, 2027. The company has appointed veteran executive Ken Kel…